Acute onset of severe dilated cardiomyopathy during bromocriptine therapy

Prashant Kaushik, Sundararama R. Vatsavai, Venkatramana R. Banda, Pramod K. Sanghi, Masood Ahmad, Richa Kaushik

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma. CASE SUMMARY: A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in the left-ventricular ejection fraction in the absence of any other identifiable causes of DCMP such as a peripartum state, ethanol use, preceding systemic viral illness, chronic hypocalcemia, chronic hypophosphatemia, or chronic uncontrolled tachycardia. She improved substantially (both symptomatically and echocardiographically) after cessation of bromocriptine therapy and initiation of supportive treatment of congestive heart failure (CHF). She showed no recurrence of CHF at a follow-up visit 2 months after withdrawal of the supportive care. The patient was not rechallenged with bromocriptine due to the clinical/ethical gravity of this probable adverse effect. DISCUSSION: Although cardiopulmonary adverse effects have been reported with the use of cabergoline (another dopamine agonist), to the best of our knowledge, this is the first case report of severe life-threatening DCMP associated with bromocriptine therapy. Causality assessment using the Naranjo probability scale revealed that the adverse drug event was probable. CONCLUSIONS: Bromocriptine was probably associated with DCMP in a patient being treated for a microprolactinoma. Severe DCMP needs to be considered a potentially life-threatening but reversible adverse effect of bromocriptine therapy for microprolactinoma of the pituitary gland.

Original languageEnglish (US)
Pages (from-to)1219-1221
Number of pages3
JournalAnnals of Pharmacotherapy
Volume38
Issue number7-8
DOIs
StatePublished - Jul 2004

Fingerprint

Bromocriptine
Dilated Cardiomyopathy
Prolactinoma
Therapeutics
Heart Failure
Hypophosphatemia
Peripartum Period
Hypocalcemia
Dopamine Agonists
Gravitation
Pituitary Gland
Drug-Related Side Effects and Adverse Reactions
Tachycardia
Causality
African Americans
Stroke Volume
Heart Ventricles
Chronic Disease
Ethanol
Recurrence

Keywords

  • Bromocriptine
  • Congestive heart failure
  • Dilated cardiomyopathy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kaushik, P., Vatsavai, S. R., Banda, V. R., Sanghi, P. K., Ahmad, M., & Kaushik, R. (2004). Acute onset of severe dilated cardiomyopathy during bromocriptine therapy. Annals of Pharmacotherapy, 38(7-8), 1219-1221. https://doi.org/10.1345/aph.1E075

Acute onset of severe dilated cardiomyopathy during bromocriptine therapy. / Kaushik, Prashant; Vatsavai, Sundararama R.; Banda, Venkatramana R.; Sanghi, Pramod K.; Ahmad, Masood; Kaushik, Richa.

In: Annals of Pharmacotherapy, Vol. 38, No. 7-8, 07.2004, p. 1219-1221.

Research output: Contribution to journalArticle

Kaushik, P, Vatsavai, SR, Banda, VR, Sanghi, PK, Ahmad, M & Kaushik, R 2004, 'Acute onset of severe dilated cardiomyopathy during bromocriptine therapy', Annals of Pharmacotherapy, vol. 38, no. 7-8, pp. 1219-1221. https://doi.org/10.1345/aph.1E075
Kaushik, Prashant ; Vatsavai, Sundararama R. ; Banda, Venkatramana R. ; Sanghi, Pramod K. ; Ahmad, Masood ; Kaushik, Richa. / Acute onset of severe dilated cardiomyopathy during bromocriptine therapy. In: Annals of Pharmacotherapy. 2004 ; Vol. 38, No. 7-8. pp. 1219-1221.
@article{f22a60d268f64e0babe8ff11a061685d,
title = "Acute onset of severe dilated cardiomyopathy during bromocriptine therapy",
abstract = "OBJECTIVE: To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma. CASE SUMMARY: A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in the left-ventricular ejection fraction in the absence of any other identifiable causes of DCMP such as a peripartum state, ethanol use, preceding systemic viral illness, chronic hypocalcemia, chronic hypophosphatemia, or chronic uncontrolled tachycardia. She improved substantially (both symptomatically and echocardiographically) after cessation of bromocriptine therapy and initiation of supportive treatment of congestive heart failure (CHF). She showed no recurrence of CHF at a follow-up visit 2 months after withdrawal of the supportive care. The patient was not rechallenged with bromocriptine due to the clinical/ethical gravity of this probable adverse effect. DISCUSSION: Although cardiopulmonary adverse effects have been reported with the use of cabergoline (another dopamine agonist), to the best of our knowledge, this is the first case report of severe life-threatening DCMP associated with bromocriptine therapy. Causality assessment using the Naranjo probability scale revealed that the adverse drug event was probable. CONCLUSIONS: Bromocriptine was probably associated with DCMP in a patient being treated for a microprolactinoma. Severe DCMP needs to be considered a potentially life-threatening but reversible adverse effect of bromocriptine therapy for microprolactinoma of the pituitary gland.",
keywords = "Bromocriptine, Congestive heart failure, Dilated cardiomyopathy",
author = "Prashant Kaushik and Vatsavai, {Sundararama R.} and Banda, {Venkatramana R.} and Sanghi, {Pramod K.} and Masood Ahmad and Richa Kaushik",
year = "2004",
month = "7",
doi = "10.1345/aph.1E075",
language = "English (US)",
volume = "38",
pages = "1219--1221",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "7-8",

}

TY - JOUR

T1 - Acute onset of severe dilated cardiomyopathy during bromocriptine therapy

AU - Kaushik, Prashant

AU - Vatsavai, Sundararama R.

AU - Banda, Venkatramana R.

AU - Sanghi, Pramod K.

AU - Ahmad, Masood

AU - Kaushik, Richa

PY - 2004/7

Y1 - 2004/7

N2 - OBJECTIVE: To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma. CASE SUMMARY: A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in the left-ventricular ejection fraction in the absence of any other identifiable causes of DCMP such as a peripartum state, ethanol use, preceding systemic viral illness, chronic hypocalcemia, chronic hypophosphatemia, or chronic uncontrolled tachycardia. She improved substantially (both symptomatically and echocardiographically) after cessation of bromocriptine therapy and initiation of supportive treatment of congestive heart failure (CHF). She showed no recurrence of CHF at a follow-up visit 2 months after withdrawal of the supportive care. The patient was not rechallenged with bromocriptine due to the clinical/ethical gravity of this probable adverse effect. DISCUSSION: Although cardiopulmonary adverse effects have been reported with the use of cabergoline (another dopamine agonist), to the best of our knowledge, this is the first case report of severe life-threatening DCMP associated with bromocriptine therapy. Causality assessment using the Naranjo probability scale revealed that the adverse drug event was probable. CONCLUSIONS: Bromocriptine was probably associated with DCMP in a patient being treated for a microprolactinoma. Severe DCMP needs to be considered a potentially life-threatening but reversible adverse effect of bromocriptine therapy for microprolactinoma of the pituitary gland.

AB - OBJECTIVE: To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma. CASE SUMMARY: A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in the left-ventricular ejection fraction in the absence of any other identifiable causes of DCMP such as a peripartum state, ethanol use, preceding systemic viral illness, chronic hypocalcemia, chronic hypophosphatemia, or chronic uncontrolled tachycardia. She improved substantially (both symptomatically and echocardiographically) after cessation of bromocriptine therapy and initiation of supportive treatment of congestive heart failure (CHF). She showed no recurrence of CHF at a follow-up visit 2 months after withdrawal of the supportive care. The patient was not rechallenged with bromocriptine due to the clinical/ethical gravity of this probable adverse effect. DISCUSSION: Although cardiopulmonary adverse effects have been reported with the use of cabergoline (another dopamine agonist), to the best of our knowledge, this is the first case report of severe life-threatening DCMP associated with bromocriptine therapy. Causality assessment using the Naranjo probability scale revealed that the adverse drug event was probable. CONCLUSIONS: Bromocriptine was probably associated with DCMP in a patient being treated for a microprolactinoma. Severe DCMP needs to be considered a potentially life-threatening but reversible adverse effect of bromocriptine therapy for microprolactinoma of the pituitary gland.

KW - Bromocriptine

KW - Congestive heart failure

KW - Dilated cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=3042638960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042638960&partnerID=8YFLogxK

U2 - 10.1345/aph.1E075

DO - 10.1345/aph.1E075

M3 - Article

VL - 38

SP - 1219

EP - 1221

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 7-8

ER -